Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($7.42) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.01 million for the quarter.
Jupiter Neurosciences Stock Performance
NASDAQ:JUNS traded down $0.23 during mid-day trading on Tuesday, hitting $1.47. 2,982 shares of the company’s stock traded hands, compared to its average volume of 315,479. The firm’s 50 day simple moving average is $2.67 and its 200 day simple moving average is $17.61. The company has a market cap of $1.33 million, a PE ratio of -0.08 and a beta of 1.87. Jupiter Neurosciences has a 1 year low of $1.55 and a 1 year high of $101.25.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on JUNS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Monday, September 21st. Wall Street Zen raised Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Jupiter Neurosciences presently has a consensus rating of “Sell”.
Get Our Latest Report on Jupiter Neurosciences
Institutional Trading of Jupiter Neurosciences
A hedge fund recently raised its position in Jupiter Neurosciences stock. Vestor Capital LLC increased its holdings in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Free Report) by 144,607.2% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 970,985 shares of the company’s stock after purchasing an additional 970,314 shares during the quarter. Vestor Capital LLC owned 2.68% of Jupiter Neurosciences worth $365,000 as of its most recent filing with the SEC.
About Jupiter Neurosciences
Jupiter Neurosciences is a clinical-stage biotechnology company developing treatments for neurodegenerative and other central nervous system disorders, as well as certain rare diseases. Its research centers on neuroinflammation and the potential therapeutic effects of resveratrol. The company’s lead product candidate, JOTROL, is a proprietary oral formulation of resveratrol designed to improve its absorption. JOTROL is investigational and is being studied for potential use in conditions including mucopolysaccharidosis type I and Friedreich’s ataxia; it is not an approved treatment.
Read More
- Five stocks we like better than Jupiter Neurosciences
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
